Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Differentiated Visceral Fat Reduction in Early Trials of WVE-007
New clinical evidence shows meaningful visceral fat reduction with a single dose of an investigational therapy. A single 240 mg dose of WVE-007, an investigational INHBE GalNAc-siRNA (SpiNA design), produced continued placebo-adjusted reductions in visceral fat mass (−14.3%; p<0.05) and total ...
Impact of Insulin Copay Caps on Medicare Beneficiary Health and Spending
In this update, we highlight a JAMA Internal Medicine article that analyzed the real-world impact of insulin copay caps on Medicare beneficiaries with type 2 diabetes. According to a new study, these policies have successfully lowered out-of-pocket insulin costs and improved adherence among exist...
Advancing the Biosimilar Approval Framework: A Shift Towards Analytical Comparability
Below we highlight how the European Medicines Agency (EMA) is reshaping the biosimilar approval framework by prioritising advanced analytical characterisation over traditional comparative efficacy studies. A recently finalized reflection paper outlines a science-based, tailored clinical develo...